Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Karolinska Development AB: Year-end Report - January-December 2024
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...
Pharm Exec18h
Q&A: Gain Therapeutics CEO Discuss AI-Driven Drug Discovery, Strategic Growth Plans
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...
manilatimes22h
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company's FDA discussions confirmed that relapse-free survival ...